Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Leases (2022 - 2026)

Ovid Therapeutics filings provide 5 years of Current Leases readings, the most recent being $1.5 million for Q1 2026.

  • Quarterly Current Leases rose 7.28% to $1.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Mar 2026, up 7.28% year-over-year, with the annual reading at $1.4 million for FY2025, 7.26% up from the prior year.
  • Current Leases hit $1.5 million in Q1 2026 for Ovid Therapeutics, up from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.5 million in Q1 2026 and bottomed at $533946.0 in Q4 2022.
  • Average Current Leases over 5 years is $1.2 million, with a median of $1.3 million recorded in 2024.
  • The largest annual shift saw Current Leases surged 133.36% in 2023 before it rose 7.2% in 2025.
  • Ovid Therapeutics' Current Leases stood at $533946.0 in 2022, then surged by 133.36% to $1.2 million in 2023, then grew by 7.22% to $1.3 million in 2024, then rose by 7.26% to $1.4 million in 2025, then increased by 1.81% to $1.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Current Leases are $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025).